Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Mikko A. I. Keränen"'
Autor:
Suvi P. M. Douglas, Atte K. Lahtinen, Jessica R. Koski, Lilli Leimi, Mikko A. I. Keränen, Minna Koskenvuo, Caroline A. Heckman, Kirsi Jahnukainen, Esa Pitkänen, Ulla Wartiovaara-Kautto, Outi Kilpivaara
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Despite recent progress in acute lymphoblastic leukemia (ALL) therapies, a significant subset of adult and pediatric ALL patients has a dismal prognosis. Better understanding of leukemogenesis and recognition of germline genetic changes may
Externí odkaz:
https://doaj.org/article/65565a374821414dab854c43e940b4e9
Autor:
Daehong Kim, Giljun Park, Jani Huuhtanen, Sofie Lundgren, Rajiv K. Khajuria, Ana M. Hurtado, Cecilia Muñoz-Calleja, Laura Cardeñoso, Valle Gómez-García de Soria, Tzu Hua Chen-Liang, Samuli Eldfors, Pekka Ellonen, Sari Hannula, Matti Kankainen, Oscar Bruck, Anna Kreutzman, Urpu Salmenniemi, Tapio Lönnberg, Andrés Jerez, Maija Itälä-Remes, Mikko Myllymäki, Mikko A. I. Keränen, Satu Mustjoki
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-17 (2020)
Chronic graft versus host disease (cGvHD) is a major cause of morbidity and mortality in allogeneic bone marrow transplantation. Here the authors identify a recurrent activating mTOR mutation in expanded donor T-cell clones of 3 cGvHD patients, which
Externí odkaz:
https://doaj.org/article/ea0ed950dd9b43599b0f71b6f958e251
Autor:
Hanna L. M. Rajala, Veli-Jukka Anttila, Mikko Haapio, Mikko A. I. Keränen, Ulla Wartiovaara-Kautto, Riikka Räty
Publikováno v:
Case Reports in Hematology, Vol 2021 (2021)
Gemtuzumab-ozogamicin (GO) is a humanized anti-CD33 antibody, which is conjugated to a cytotoxic calicheamicin. It is used to treat acute myeloid leukemia (AML) in combination with chemotherapy. We describe here two GO-treated acute myeloid leukemia
Externí odkaz:
https://doaj.org/article/3b672f54672f49918c8d96fb2cedac09
Autor:
Paula Savola, Sofie Lundgren, Mikko A. I. Keränen, Henrikki Almusa, Pekka Ellonen, Marjatta Leirisalo-Repo, Tiina Kelkka, Satu Mustjoki
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-2 (2021)
A Correction to this paper has been published: https://doi.org/10.1038/s41408-021-00427-1
Externí odkaz:
https://doaj.org/article/418900144a7442d4940ce350eb346f49
Autor:
Disha Malani, Satu Mustjoki, Olli Lohi, Matti Kankainen, Kirsi J. Granberg, Olli Dufva, Mikko A. I. Keränen, Markus Vähä-Koskela, Merja Heinäniemi, Bishwa Ghimire, Matti Nykter, Sirpa Leppä, Ashwini Kumar, Leo Meriranta, Pirkko Mattila, Petri Pölönen, Juha Mehtonen, Suvi-Katri Leivonen, Krister Wennerberg, Oscar Brück, Jay Klievink, Sanna Siitonen, Jani Huuhtanen, Caroline A. Heckman, Jenni Lahtela
Publikováno v:
Cancer Cell. 38:424-428
Understanding factors that shape the immune landscape across hematological malignancies is essential for immunotherapy development. We integrated over 8,000 transcriptomes and 2,000 samples with multilevel genomics of hematological cancers to investi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19ff4ee7a109e3a2aac727d48bd4b02f
https://doi.org/10.1016/j.ccell.2020.08.019
https://doi.org/10.1016/j.ccell.2020.08.019
Autor:
Hanna Rajala, Mikko A. I. Keränen, Riikka Räty, Veli-Jukka Anttila, Ulla Wartiovaara-Kautto, Mikko Haapio
Publikováno v:
Case Reports in Hematology, Vol 2021 (2021)
Case Reports in Hematology
Case Reports in Hematology
Gemtuzumab-ozogamicin (GO) is a humanized anti-CD33 antibody, which is conjugated to a cytotoxic calicheamicin. It is used to treat acute myeloid leukemia (AML) in combination with chemotherapy. We describe here two GO-treated acute myeloid leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be7ac6646119ea8d6b2e640716beaf82
http://hdl.handle.net/10138/330556
http://hdl.handle.net/10138/330556
Autor:
Timi Martelius, Janna Saarela, Matti Kankainen, Soili Kytölä, Pekka Ellonen, Yrjö Koski, Samuli Eldfors, Jani Huuhtanen, Tiina Kelkka, Panu E. Kovanen, Harri Lähdesmäki, Satu Mustjoki, Mikko Seppänen, Sofie Lundgren, Mikko A. I. Keränen, Paula Savola
Publikováno v:
Haematologica
Common variable immunodeficiency and other late-onset immunodeficiencies often co-manifest with autoimmunity and lymphoproliferation. The pathogenesis of most cases is elusive, as only a minor subset harbors known monogenic germline causes. The invol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d882f3527c539ff78b698ab6682f9f9c
https://aaltodoc.aalto.fi/handle/123456789/101627
https://aaltodoc.aalto.fi/handle/123456789/101627
Autor:
Satu Mustjoki, Pekka Ellonen, Eva Hellström-Lindberg, Hanna Rajala, Sofie Lundgren, Jaroslaw P. Maciejewski, Freja Ebeling, Cassandra M Kerr, Neal S. Young, Gunilla Walldin, Sari Hannula, Matti Kankainen, Jani Huuhtanen, Oscar Brück, Harri Lähdesmäki, Mikko A. I. Keränen, Seishi Ogawa, Tiina Hannunen, Michael J. Clemente
Publikováno v:
Leukemia
Funding Information: Acknowledgements The authors would like to thank Hanna Läh-teenmäki, Tiina Kasanen, and Jay Klievink from the Hematology Research Unit Helsinki for valuable technical assistance. The authors would also like to thank Noora Aarni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58cc8cc42ea1df22a60a4886068a39a9
https://pubmed.ncbi.nlm.nih.gov/33785863
https://pubmed.ncbi.nlm.nih.gov/33785863
Autor:
Ana María Hurtado, Satu Mustjoki, Urpu Salmenniemi, Jani Huuhtanen, Pekka Ellonen, Rajiv K. Khajuria, Mikko Myllymäki, Matti Kankainen, Daehong Kim, Sofie Lundgren, Mikko A. I. Keränen, Giljun Park, Maija Itälä-Remes, Tzu Hua Chen-Liang, Andres Jerez, Samuli Eldfors, Laura Cardeñoso, Sari Hannula, Oscar Brück, Anna Kreutzman, Valle Gómez García de Soria, Tapio Lönnberg, Cecilia Muñoz-Calleja
Publikováno v:
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid
Nature Communications, Vol 11, Iss 1, Pp 1-17 (2020)
Nature Communications
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Universidad Autónoma de Madrid
Nature Communications, Vol 11, Iss 1, Pp 1-17 (2020)
Nature Communications
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Graft versus host disease (GvHD) is the main complication of allogeneic hematopoietic stem cell transplantation (HSCT). Here we report studies of a patient with chronic GvHD (cGvHD) carrying persistent CD4 T cell clonal expansion harboring somatic mT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80004dc6bc4cf39c734b43d69bf77021
https://doi.org/10.1038/s41467-020-16115-w
https://doi.org/10.1038/s41467-020-16115-w
Autor:
Alireza Raissadati, Simo Syrjälä, Mikko A. I. Keränen, Rainer Krebs, Alexey Dashkevich, Raimo Tuuminen, Antti I. Nykänen, Randall S. Johnson, Karl B. Lemström
Publikováno v:
Transplant International. 32:95-106
Hypoxia-inducible factors (HIFs) play a critical role in inflammatory properties of myeloid-derived cells. The effect of HIFs on myeloid-derived cell functions in organ transplantation remains unknown, however. We transplanted hearts into transgenic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61570e0d2cb876d26dc57b3b69350def
https://doi.org/10.1111/tri.13310
https://doi.org/10.1111/tri.13310